This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Treatment

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Seek expert advice

Most leptospirosis cases are mild and resolve spontaneously (1)

  • early initiation of antimicrobial therapy may prevent some patients from progressing to more severe disease.

Penicillin or tetracylines should be given within the first 5 days of the illness

  • therapy for patients with leptospirosis severe enough to merit hospitalization usually involves intravenous penicillin (1.5 million units IV every 6 h), ampicillin (0.5-1 g IV every 6 h), ceftriaxone (1 g IV every 24 h), or cefotaxime (1 g IV every 6 h) (1)
  • adult outpatients with early disease should receive either doxycycline 100 mg orally twice per day or azithromycin 500 mg orally once per day (1)

Further management is supportive with special attention to fluid balance and the possible need for renal replacement therapy.

Doxycycline is a useful prophylaxis that may be given to high risk groups.

Reference:

  • Haake DA, Levett PN. Leptospirosis in humans. Curr Top Microbiol Immunol. 2015;387:65-97

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.